Li Zhang, Ph.D.

Li concentrates on patent litigation, focusing on Biologics Price Competition and Innovation Act (BPCIA) and Abbreviated New Drug Application (ANDA) litigation and on post-grant proceedings (e.g., post-grant review (PGR), inter partes review (IPR)) before the USPTO’s Patent Trial and Appeal Board (PTAB). Prior to rejoining Finnegan, Li clerked for the U.S. Court of Appeals for the Federal Circuit and the U.S. District Court for the District of Delaware, both with Judge Leonard P. Stark, and assisted the latter venue in managing one of the nation’s busiest patent dockets.

Li’s practice extends to portfolio assessment and strategic client counseling. He has conducted thorough research in cellular and molecular biology and co-authored more than a dozen peer-reviewed publications in scientific journals. Li is well-versed in technologies across the life science fields and has assisted clients in patent prosecution, strategic counseling, and freedom-to-operate (FTO) analysis on complex subject matters, including antibodies, antibody-drug conjugates, gene editing (e.g., CRISPR), gene therapy, modified polynucleotides, drug delivery, and compound biosynthesis.